“Sid has proven his considerable value to the company in his seven years with us, and has been rewarded with steadily increasing levels of responsibility along the way,” said Patrick M. Dentinger, President and CEO of Absorption Systems. “As Chief Operating Officer his passion, focus and drug development savvy will help us execute our shared vision for the future of Absorption Systems.”
Previously, Dr. Bhoopathy was a research scientist at PPDI, focusing on developing and validating GLP analytical methods and performing metabolite identification using high-resolution mass spectrometry. He received his Ph.D. in pharmaceutics from Virginia Commonwealth University. His current research interests are in the areas of blood-brain barrier (BBB), Biopharmaceutics Classification System (BCS) and drug transporters.
“Absorption Systems is a world leader in several areas,” said Dr. Bhoopathy, “and I’m really excited about continuing to grow the company’s top line and bottom line, and further enhancing its reputation for scientific excellence.”
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies® platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company's comprehensive contract services and applied research programs, please visit www.absorption.com.
